I
nflammatory bowel diseases (IBD), encompassing Crohn's disease and ulcerative colitis (UC), are incurable, relapsing, and remitting intestinal diseases that often require chronic medication usage to maintain remission. 1 Adherence is 'the extent to which the patient's behavior matches agreed recommendations from the prescriber'. 2 Medication nonadherence occurs in up to 45% of patients with IBD, and is associated with disease exacerbations, poorer clinical outcomes, increased healthcare utilization, and increased economic burden. [3] [4] [5] [6] Medication nonadherence is divided into intentional and unintentional causes. Unintentional nonadherence implies forgetfulness or obstacles in obtaining medications. The frequency of unintentional nonadherence is typically ,1 dose per week and unlikely to result in clinically significant sequelae. 7 Intentional nonadherence, however, is a deliberate decision to stop maintenance medications. This is often driven by a patient's perception of the necessity of medications or concerns about their side effects. [8] [9] [10] The Health Beliefs Model is a well-established and validated construct of medication perception and attitude. It quantitates the 2 domains of Necessity and Concern. Medication "acceptance" is defined as perception of high necessity and low concerns toward medications, and is strongly associated with adherence (see Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B553). 8, [10] [11] [12] [13] [14] Modification of attitudes Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
toward medicines through the health beliefs model has the potential to improve medication adherence. 5, 10 This, however, has not been tested in IBD.
To date, strategies that aim to improve adherence to IBD maintenance medication have not resulted in a successful and easily implementable solution. Education using pamphlets and ad hoc physician education improved knowledge but not adherence. 15 A nurse-delivered patient support program neither improved medication adherence nor patients' quality of life. 16 These interventions, at best, target unintentional nonadherence through introducing reminder systems. They, however, fail to address intentional nonadherence, which requires personalized counseling to address underlying misperceptions of medication necessity or concerns over adverse effects. A multifaceted interventional study 17 choosing up to 3 adherence-enhancing interventions from a choice of 7, and being permitted to change these interventions at any time during the study, significantly maintained high adherence (76%) in comparison to the control group (32%, P ¼ 0.001). However, nonadherers at baseline remained nonadherent at the end of the study, indicating that this intervention was ineffective in improving nonadherence. 17 The complexity of the study design prohibited a clear strategy to be implemented and only tested 5-aminosalicylate (5-ASA) adherence in UC. Another small scale trial found that telephone support and encouragement can improve adherence in the short term, once again in patients with UC on 5-ASA. 18 However, whether an intervention can improve adherence and be sustained in baseline nonadherers, or whether strategies can be generalized to the full spectrum of medications used in IBD, is currently unknown.
The IBD Pharmacist Adherence Counselling (IPAC) intervention comprises a single-personalized counseling session with nonadherent patients with IBD conducted by a clinical IBD pharmacist. Pilot data demonstrated an increase in medication adherence at 3 months of follow-up. 19 The long-term durability of the benefit of IPAC has not previously been studied. This proof of concept study had the primary aim to investigate the effects of IPAC on medication adherence in nonadhering patients with IBD compared against adherers on longitudinal follow-up. Secondary outcome measures were assessments on the subjects' Necessity and Concern Beliefs about Medicines Questionnaire (BMQ) scores, and medication acceptance rates, and clinical effects on flares of IBD in comparison with baseline medication adherers.
PATIENTS AND METHODS

Study Design
This was a multicenter prospective longitudinal parallel interventional study. Consecutive IBD subjects were determined to be either medication "baseline non-adherers" or "baseline adherers". Baseline nonadherers received the IPAC intervention ("IPAC arm") and adherers at baseline were "controls." Both groups were followed longitudinally for 24 months. The primary outcome was the change in medication adherence rates following the IPAC intervention and its durability to 24 months. The secondary outcomes were perception of medication necessity and concerns and the medication acceptance rates. Clinical outcomes were also measured to determine the proportion of subjects requiring medical or surgical treatment escalation during the follow-up period.
Subjects
Subjects were recruited from the IBD Services of Concord Hospital, Bankstown Hospital and Macquarie University Hospital, which form part of the IBD Sydney group in Australia. Consecutive subjects aged 18 to 70 years that met the inclusion criteria were prospectively recruited. The inclusion criteria were Crohn's disease or UC of at least 6 months' duration according to standard endoscopy, radiology, and histology criteria, and being prescribed maintenance IBD medications including 5-aminosalicylate, immunomodulators, and/or biological agents. Subjects had stable disease activity and were not undergoing evaluation for surgery or a clinical drug trial. Exclusion criteria were not being on maintenance medications or on temporary medications only (such as short course corticosteroids or for planned surgery), refusal to participate in the study or followup, poor understanding of the questionnaires, or active disease prompting treatment escalation.
All subjects provided written informed consent. The study was approved by Sydney Local Health District (CH62/6/2011-147) and registered under the Australia New Zealand Clinical Trials Registry (ACTRN12616000094471).
Medication Adherence Report Scale
The Medication Adherence Report Scale (MARS) questionnaire was screened for nonadherence. In the absence of formal validation studies, the MARS questionnaire has been well used in IBD and other chronic diseases. 10, 12, 14, 20 Items are scored on a 5-point Likert scale and summed to yield a total score between 4 and 20 (see Table 1 , Supplemental Digital Content 2, http:// links.lww.com/IBD/B554). Participants scoring #16 were classified as nonadherers, and $17 were classified as adherers according to established definitions. 10 
Beliefs About Medicines Questionnaire
The perception and attitude on prescribed IBD medications was assessed with the validated BMQ. 12 This questionnaire has two 5-item subscales which assess the patient's beliefs about the necessity of medications in managing illness and concerns relating to side effects of the medication, respectively. An example of a Necessity question is "My health in the future will depend on these medicines." An example of a Concern question is "Having to take these medicines worries me." Each question is scored on a 5-point Likert scale: Totally agree (5), Agree somewhat (4), Neither agree nor disagree (3), Disagree somewhat (2), and Disagree totally (1) . Each subscale is summated to yield a total score from 5 to 25, with 15 to 25 defined as high Necessity or Concern scores. Medication "acceptance," defined as having high Necessity and low Concern scores, has been demonstrated to correlate with improved medication adherence.
IPAC Intervention
Nonadherent patients received a structured personalized counseling session with an IBD pharmacist addressing medication-related misperceptions, concerns, risks, and other queries. Strategies that improve both unintentional and intentional nonadherence were covered either face-to-face or by telephone as preferred by the subject. Counseling was designed to be independent to the medical consultation, and the pharmacist was seen as a medication expert removed from the prescribing doctor. This strategy encouraged subjects to be honest and not feel the need to exaggerate their adherence to avoid the disappointment of the prescribing doctor. The educational intervention focused on IBD medications, using the Health Beliefs Model to identify barriers and to develop strategies that target both unintentional and intentional nonadherence. It was conducted in a permissive environment aiming at a joint consensus on medication use between the IBD team and the subject. Follow-up telephone counseling was permitted to reinforce information once, but typically was not required. Thereafter, there was no further counseling on subsequent visits or telephone calls. Baseline adherers (MARS $ 17) were recruited as controls and did not receive the IPAC intervention. The IPAC and the control arms were followed up longitudinally with MARS and BMQ repeated at 6-monthly intervals through telephone by a blinded researcher. For data reduction and simplification, we present the results at 12 and 24 months.
Sample Size Calculation
A prior study 17 demonstrated an increase in adherence from 32% in the control group to 76% in the multifaceted interventional group. Using this, to achieve 90% power and an a ¼ 0.05, a sample size of 29 was needed. An additional 7 (20%) patients were recruited to account for drop out over the 2-year study period. Missing data were accounted for by the last-observation-carriedforward method.
Statistical Analysis
Analyses were performed on the basis of the intention-totreat principle. Standard descriptive statistics were used for measured and derived variables. The Chi square test was used for categorical variables; the Mann-Whitney U test for unpaired nonparametric continuous variables; and the Wilcoxon signed rank test for paired continuous variables. Spearman correlation test was used for nonparametric continuous variables. McNemars' test was used for paired dichotomous dependent variables. Proportions were described as percentages and 95% confidence intervals (CIs). A P value of ,0.05 was deemed statistically significant. Post hoc subgroup analyses were done subdividing nonadherers into the following groups (MARS ¼ 16, MARS ¼ 14-15, and MARS ,14). All data were analyzed with the use of IBM SPSS Statistics software Version 20.
RESULTS
In total, 114 patients were screened, and of these 8 subjects declined participation, 2 were not on maintenance medications, and 4 subjects failed to complete baseline questionnaires. In total, 100 subjects were enrolled with 36 (36.0%) as baseline nonadherers and 64 (64.0%) as baseline adherers (see Fig. 2 , Supplemental Digital Content 3, http:// links.lww.com/IBD/B555). Overall, 52.0% of patients were female, and 66.0% had Crohn's disease. Maintenance medications comprised 5-aminosalicylic acid (52.0%), immunomodulators (63.0%), and biological agents (30.0%). Baseline characteristics including demographics, diagnosis, and composition of IBD maintenance medications were similar between both groups (see Table 2 , Supplemental Digital Content 4, http://links.lww.com/IBD/B556). No relationship between the characteristics listed in Table 3 and adherence was found. The overall median follow-up was 24 months.
Adherence and MARS
The baseline median MARS of IPAC and controls were 15.0 and 19.0 (P , 0.001). At 24 months nonadherence, rates of baseline nonadherers had decreased from 100% to 44.4% (P ¼ 0.001). Median MARS improved from 16.0 to 17.0 (P , 0.001) at 12 months and at 24 months. Baseline adherers adherence rates remained stable over the study period (12 months: P ¼ 0.636; 24 months: P ¼ 0.377). By the end of the study, median MARS of the IPAC and control arms were 17.0 and 19.5 (P ¼ 0.001; see 
Medication Necessity and Concerns
Baseline medication median Necessity scores were 20 for baseline nonadherers and 22 for baseline adherers (P ¼ 0.08), and no significant changes from baseline were seen in both groups on follow-up (P ¼ 0.60 and P ¼ 0.62 respectively). Baseline medication median Concern score for both groups was 16 (P ¼ 0.92). Concern scores also remained unchanged in both groups at 24 months (non-adherer P ¼ 0.64, adherer P ¼ 0.15).
Acceptance
Baseline medication acceptance rates were 42.2% 95% CI (30.1, 54.3) for baseline adherers and 36.1% 95% CI (20.4, 51.8) for baseline nonadherers. (P ¼ 0.55) Baseline nonadherers significantly increased their medication acceptance scores to 52.8% 95% CI (36.5, 69.1) at 12 months (P ¼ 0.031) with a trend toward sustained significance at 24 months (P ¼ 0.063). For baseline adherers, medication acceptance rates was 44.8% 95% CI (32.6, 57.0) by the end of follow-up (P ¼ 0.50).
Adherence and Clinical Relapse of IBD
In baseline adherers, 23/64 (35.9%) patients suffered disease relapse as evidenced by the need for medical or surgical treatment escalation over a follow-up period of 2 years. In baseline nonadherers receiving IPAC intervention, 10/36 (27.8%) subjects recorded disease relapse requiring treatment escalation (P ¼ 0.40).
DISCUSSION
Nonadherence occurs in up to 45% of IBD subjects and leads to increased disease relapse and health care utilization. 6 To date, attempts at managing nonadherence have focused on improving unintentional nonadherence without sufficiently or systematically addressing intentional nonadherence. 15, 17 This is the first study to demonstrate that intentional nonadherence can be successfully addressed and was durable to 2 years. As this intervention only involves personalized counseling at baseline, it is feasible with a low cost burden.
There are many strengths to this study. Previous studies have focused on only 5-aminosalicylates, 4, 16, 17 whereas this study demonstrated effectiveness across the spectrum of IBD maintenance medications. We found that delivery of the validated questionnaire tools 10 and the IPAC intervention by a third-party clinical pharmacist encouraged patients to be honest with their responses, avoiding the embarrassment of discussing adherence with their prescribers. IPAC identifies and targets the motivation of nonadherence; either the perception that medications are not necessary and/or concerns of potential risks and side effects. Repeated IPAC sessions and provision of supplemental materials may further improve the effectiveness of the intervention, but was not tested in this proof of concept study.
The IPAC intervention led to significantly increased medication acceptance rate in nonadherers for up to 24 months. A previous cross-sectional survey of 1871 patients found that patients accepting of their medications were significantly more likely to be adherent to medications. 10 The adherence rates of baseline nonadherers at 24 months do not reach the level of baseline adherers. Nonadherence may only be partially improved through counseling, and other factors, such as concurrent anxiety or depression, may require specific management by a clinical psychologist. This is the subject of an ongoing clinical study.
Another important finding is that baseline adherers continued to be adherent with favorable BMQ scores throughout the study period. This population tends to reflect a compliant personality trait, which embraces and understands the need for medications and ongoing maintenance therapy. No previous studies had longitudinally followed medication adherers and whether they modify their medication perception over time. The translatable benefit of this study, therefore, is that there is little to no need to monitor adherence in baseline adherers over time, which allows clinicians to focus resources on nonadherent patients. This study has several limitations. Firstly, although there is no gold standard to assess adherence, the use of validated selfreport adherence questionnaires has been shown to better predictors of high adherence rather than poor adherence compared with other adherence measures. 21 To ensure generalizability, subjects recruited were taking all classes of IBD maintenance medications and avoided the need to measure multiple drug assays. Standardized questionnaires are less invasive and restrictive and more likely to be reproducible on an intraindividual basis on follow-up. 2, 10, 21 Secondly, loss of patients to follow-up was unavoidable in prospective longitudinal studies. However, there were no significant differences of patients with and without final data, and statistical imputation was applied to deliver conservative endpoint assessments. At the same time, the follow-up period of 2 years demonstrated durability of the IPAC intervention. The IPAC intervention showed the greatest efficacy on those with lower MARS scores (MARS ,14) on subanalysis. The study might be underpowered to detect statistically significant differences in those with higher MARS scores. Thirdly, although clinical relapse rate was numerically lower in the IPAC group than the control group, the study was not powered to detect statistical difference. Finally, the act of measuring adherence may influence the behavior and cause self-presentational bias. 2 However, the use of a third-party health care professional independent to the prescribing doctor helps to reduce this phenomenon. This might result in less pressure to deliver socially responsible responses. Further testing of the intervention using a large scale randomized controlled trial would definitively demonstrate the impact of IPAC on adherence.
CONCLUSIONS
In conclusion, medication nonadherence in IBD is a dynamic factor that can improve through a single counseling session by a trained pharmacist based on the Health Beliefs Model. This was durable on follow-up and effective for all classes of IBD medication. Its efficacy appeared greatest for those with the poorest level of adherence. Baseline adherers, on the other hand, maintain high adherence over time and may not require dedicated resource allocation for education and counseling.
